| CAS NO: | 1446712-19-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 406.35 |
|---|---|
| Formula | C21H17F3O5 |
| CAS No. | 1446712-19-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 32 mg/mL |
| Water: <1 mg/mL | |
| Ethanol: | |
| SMILES Code | FC(F)(F)C(C=C1)=CC=C1C2=C(O)C(C(C(O)=CC(O)=C3C/C=C(C)/C)=C3O2)=O |
| Synonyms | SNG1153; SNG-1153; SNG 1153 |
| In Vitro | In vitro activity: SNG-1153 is the 2nd generation small molecule for cancer therapy from Shenogen Pharma Group. SNG-1153 has inhibitory effects on TKI-resistant CML cells. Kinase Assay: Cell Assay: SNG-1153 is the 2nd generation small molecule for cancer therapy from Shenogen Pharma Group. SNG-1153 has inhibitory effects on TKI-resistant CML cells. |
|---|---|
| In Vivo | SNG1153 shows significant inhibition at low micromolar concentrations in ER-α36 overexpressed cell lines including the one resistant to tamoxifen. SNG1153 exhibited a linear PK profile with a bioavailability of more than 55% in the rat PK study. In the in-vivo efficacy studies, 3 doses were investigated and SNG1153 showed dose-dependent inhibition. The tumor growth inhibition at high dose was 57% in the breast cancer Bcap-37 xenograft model, 65% in the endometrial cancer Ishikawa xenograft model and 52% in lung adenocarcinoma SPC-A-1 xenograft model |
| Animal model | |
| Formulation & Dosage | |
| References | CN 104860993 A 20150826.; WO 2013104263 A1 20130718. |
m.cnreagent.com